The same study reveals that lipocalin-2, another tissue-derived, lipid-binding cytokine, can differentiate NAFLD from the control group as well, but it is not able to distinguish NASH from simple steatosis. This evidence concerns the gene LCN2 and metabolic dysfunction-associated steatotic liver disease.